Namilumab

Drug Profile

Namilumab

Alternative Names: MT-203

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator Micromet Inc
  • Developer Takeda Pharmaceuticals International GmbH
  • Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Plaque psoriasis; Rheumatoid arthritis

Most Recent Events

  • 01 Dec 2016 Takeda completes the TELLUS trial in Rheumatoid arthritis (Combination therapy, In adults, In elderly) in United Kingdom, Czech Republic, Estonia, Spain (EudraCT2014-002945-23)
  • 01 Nov 2016 Takeda completes the NEXUS trial in Rheumatoid arthritis (Combination therapy, In the elderly, In adults) in Bulgaria, Czech Republic, Japan, South Korea, Russia, Spain and United Kingdom (SC) (NCT02379091)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Rheumatoid-arthritis in Bulgaria (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top